Kim Mi-Sook, Kim Wonwoo, Park In Hwan, Kim Hee Jong, Lee Eunjin, Jung Jae-Hoon, Cho Lawrence Chinsoo, Song Chang W
Research Center for Radiotherapy, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Department of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN, USA.
Radiat Oncol J. 2015 Dec;33(4):265-75. doi: 10.3857/roj.2015.33.4.265. Epub 2015 Dec 30.
Despite the increasing use of stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS) in recent years, the biological base of these high-dose hypo-fractionated radiotherapy modalities has been elusive. Given that most human tumors contain radioresistant hypoxic tumor cells, the radiobiological principles for the conventional multiple-fractionated radiotherapy cannot account for the high efficacy of SBRT and SRS. Recent emerging evidence strongly indicates that SBRT and SRS not only directly kill tumor cells, but also destroy the tumor vascular beds, thereby deteriorating intratumor microenvironment leading to indirect tumor cell death. Furthermore, indications are that the massive release of tumor antigens from the tumor cells directly and indirectly killed by SBRT and SRS stimulate anti-tumor immunity, thereby suppressing recurrence and metastatic tumor growth. The reoxygenation, repair, repopulation, and redistribution, which are important components in the response of tumors to conventional fractionated radiotherapy, play relatively little role in SBRT and SRS. The linear-quadratic model, which accounts for only direct cell death has been suggested to overestimate the cell death by high dose per fraction irradiation. However, the model may in some clinical cases incidentally do not overestimate total cell death because high-dose irradiation causes additional cell death through indirect mechanisms. For the improvement of the efficacy of SBRT and SRS, further investigation is warranted to gain detailed insights into the mechanisms underlying the SBRT and SRS.
尽管近年来立体定向体部放射治疗(SBRT)和立体定向放射外科手术(SRS)的应用日益广泛,但这些高剂量低分割放疗模式的生物学基础一直难以捉摸。鉴于大多数人类肿瘤都含有耐辐射的缺氧肿瘤细胞,传统的多分次放疗的放射生物学原理无法解释SBRT和SRS的高疗效。最近出现的证据有力地表明,SBRT和SRS不仅直接杀死肿瘤细胞,还破坏肿瘤血管床,从而恶化肿瘤内微环境导致间接肿瘤细胞死亡。此外,有迹象表明,SBRT和SRS直接和间接杀死的肿瘤细胞大量释放肿瘤抗原,刺激抗肿瘤免疫,从而抑制复发和转移性肿瘤生长。再氧合、修复、再增殖和再分布是肿瘤对传统分割放疗反应的重要组成部分,在SBRT和SRS中作用相对较小。仅考虑直接细胞死亡的线性二次模型被认为高估了每次高剂量照射的细胞死亡。然而,在某些临床病例中,该模型可能偶然不会高估总细胞死亡,因为高剂量照射通过间接机制导致额外的细胞死亡。为了提高SBRT和SRS的疗效,有必要进一步研究,以深入了解SBRT和SRS的潜在机制。